AriBio Announces Completion of Dosing in POLARIS-AD Global Phase 3 Trial of AR1001 for Early Alzheimer’s Disease
Readout from the pivotal global Phase 3 trial of 1,535 participants is expected later in 2026 SAN DIEGO, CA, UNITED STATES, June 30, 2026 /EINPresswire.com/ -- AriBio Co., Ltd. today announced that the last patient has completed dosing in POLARIS-AD ( …